Azịza ngwa ngwa
Technical guide on Fmoc peptide synthesis, PEG linkers, mgbanwe mgbanwe TFA, and QC thresholds for PD-L1 targeted gold nanoparticle bioconjugation.
Fmoc Peptides maka PD-L1 ọla edo nanoparticles: Nkọwapụta & Ntuziaka QC
Ụlọ ọrụ Peptide cyclic Nnyefe ezubere iche nke ndị na-egbochi mgbochi mgbochi mgbochi na-anọchite anya otu oke oke na-arụsi ọrụ ike na oncology. Ọ bụ ezie na ọgwụ mgbochi monoclonal megide Programmed Death-Ligand 1 (PD-L1) agbanweela ọgwụgwọ ọrịa kansa, nchịkwa sistemu ha na-enwekarị oke, gụnyere adịghị mma akpụ penetration, ihe omume ọjọọ metụtara mgbochi mgbochi na-apụ apụ, na mkpochapụ ngwa ngwa. Iji merie ihe mgbochi ndị a, nyocha nanomedicine agbanweela na ngwakọ nanoconstructs-kpọmkwem, ọla edo nanoparticles (AuNPs) arụ ọrụ na sịntetik PD-L1-ezubere iche peptides.
Ụlọ ọrụ Peptide P Peptide-arụ ọrụ ọla edo nanoparticles na-enye nnukwu njikọ njikọta nke multivalent, biodistribution na-achịkwa, na mma biocompatibility. Agbanyeghị, ịtụgharị asụsụ PD-L1 peptide emebere kọmpụta ma ọ bụ ihe ngosi phage ka ọ bụrụ ụlọ anụ ụlọ., nanoconjugate na-arụ ọrụ bio-na-achọ ihe karịrị njikọ usoro siri ike nke na-aga n'ihu. Ọganihu nke nanoconjugation na-adabere kpamkpam na oke kemịkalụ dị oke egwu: ogologo njikọ, njikwa njikọ saịtị akọwapụtara, mgbochi ịdị ọcha, yana njikwa endotoxin siri ike.
Ntuziaka teknụzụ a na-akọwapụta nkọwapụta njedebe-na-ọgwụgwụ, chọrọ injinịa kemịkalụ, na njikwa mma (QC) Atụmanya maka Fmoc-synthesized peptides nke a kara aka maka njikọta nanoparticle ọla edo.
Chemistry nke Nhọrọ Target: Ihe kpatara Fmoc SPPS ji dị mma maka PD-L1 Peptides
Synthesis Peptide siri ike (SPSS) na-eji fluorenylmethyloxycarbonyl (Fmoc)/tert-butyl (t-Nke a) Atụmatụ nchebe orthogonal ka bụ ọkọlọtọ ọla edo maka imepụta peptides ezubere iche ruo 40–50 amino acid n'ogologo.. Tụnyere okwu recombinant ma ọ bụ nhazi usoro mmiri mmiri, Fmoc SPPS na-enye njikwa saịtị zuru oke maka ntinye amino acid na-abụghị eke., pseudoproline dipeptides, na aka ahaziri C-terminal ma ọ bụ N-terminal njikọ.
Imeri Ihe mgbochi Njikọta kpọmkwem Usoro
PD-L1 na-ekekọta peptides-dị ka peptides cyclic ma ọ bụ ahịrị achọpụtara site na ọba akwụkwọ nchikota-na-enwekarị ụyọkọ hydrophobic bara ụba na Tyrosine., Tryptophan, Phenylalanine, na ihe ndị ọzọ Leucine. N'oge mgbakọ agbụ ugboro ugboro na nkwado resin na-adịghị ike (dị ka Rink Amide ma ọ bụ Wang resins), Akụkụ hydrophobic ndị a na-adịkarị mfe na nchịkọta beta-ibeta nke inter-chain. Nchịkọta a na-amachibido ịnweta reagents, na-eme ka mwepu Fmoc ezughị ezu yana usoro ihichapụ ewepụghị.
Iji hụ na iguzosi ike n'ezi ihe n'usoro n'oge Fmoc SPPS:
- Nchedo & nlekota oru: A na-eme iwepụ Fmoc site na iji 20% piperidine na N,N-dimethylformamide (DMF) (v/v), A na-enyocha ya ozugbo site na ule Kaiser ninhydrin iji nyochaa mkpughe amine zuru oke tupu usoro njikọ ọ bụla..
- Njikọ Chemistry: Ngwakọta phosphonium dị elu ma ọ bụ uronium njikọ njikọ (dị ka HATU ma ọ bụ HBTU/Oxyma Pure) n'ihu N,N-diisopropylethylamine (DIPEA) A na-arụ ọrụ iji chụpụ mmeghachi omume njikọ njikọ siri ike na mmecha.
- Cocktails nke Scavenger Claavage: Nhicha sitere na nkwado resin na-eji trifluoroacetic acid (TFA) mmanya emebere ya na ndị na-akpachapụ anya—nke bụ TFA/Triisopropylsilane (TIS)/Mmiri/1,2-Ethanedithiol (EDT) (92.5/2.5/2.5/2.5 v/v). EDT ma ọ bụ DODT scavengers dị mkpa mgbe usoro peptide nwere ihe fọdụrụnụ Cysteine., na-egbochi ntinye nke trityl carbocation na ichebe otu sulfhydryl n'efu site na oxidation akaghi aka..
Njikọ Architecture & Mgbanwe Saịtị akọwapụtara maka mgbakwasị ọla edo nanoparticle
Mgbakwunye regioselective nke peptide na elu nanoparticle ọla edo dị mkpa. Njikọ saịtị ma ọ bụ ọtụtụ saịtị na-agbanwe ntụgharị oghere nke ngalaba njikọ PD-L1, occluding isi pharmacophores na mbenata nnabata njikọ njikọ.
[Usoro njikọ PD-L1] [Monodisperse PEG Linker] [Cys Thiol Handle] S AuNP
Direct Gold-Thiol (S-Awu) Nchikota
Ihe ngwọta nke sulfhydryl (-SH) otu nke ihe fọdụrụ Cysteine etolite ike, ọkara-covalent nchikota njikọ na ọla ọla edo na-ebupụta, na-enye ike njide ihe dị ka 45 kcal/mol. N'oge njikọ, A na-ewebata otu ihe fọdụrụ Cysteine kpọmkwem na saịtị C-terminus ma ọ bụ N-terminus nke usoro.. Iji gbochie intra- ma ọ bụ inter-molecular disulfide dimer nhazi tupu nanoconjugation, A ga-edobe peptides thiolated n'okpuru ọnọdụ mbelata ma ọ bụ mesoo ya na ndị na-ebelata ihe dị ka dithiothreitol. (DTT) ma ọ bụ tris(2-carboxyethyl)phosphine (TCEP) tupu mgbakwunye AuNP.
Polyethylene glycol (PEG) Injinia Spacer
Itinye PD-L1 peptide na-ekekọta ozugbo na isi ọla edo siri ike na-ebutekarị ihe mgbochi siri ike megide onye na-anabata PD-L1 cell-surface.. Iji dozie nke a, Polyethylene glycol monodisperse (PEG) A na-etinye spacer n'etiti usoro peptide na aka mgbakwasị thiol.
Akwụkwọ ndị e bipụtara na-egosi na a monodisperse PEG8 oghere (molekụla arọ ~ 649 Da) etinyere n'akụkụ agbụ nke Lysine ma ọ bụ ozugbo na C-terminus na-enye mgbanwe mgbanwe ohere kachasị mma.. Nnyocha e bipụtara na PMC Bioorganic Chemistry (2024) na-akwado na ịtinye njikọ PEG8 na-echekwa njikọ dị elu nke peptides ezubere iche nke PD-L1 ebe ọ na-agbatị ọkara ndụ plasma ma na-egbochi mgbasa ozi protein na-abụghị nke akọwapụtara. (nchekwube) na mgbede. Dabere na urughuru curvature na hydrodynamic radius, monodisperse spacers sitere na PEG2 ruo PEG36 ka ahọpụtara ka ha na-emegharị nha nke hydrodynamic na urughuru dispersibility..
Maleimide-Thiol Cross-Linking vs. Adsorption ozugbo
Mgbe functionalizing tupu-capped ọla edo nanoparticles (dị ka citrate-stabilized ma ọ bụ maleimide-PEG-arụ ọrụ AuNP), A na-eji ụzọ bioconjugation abụọ dị iche iche:
- Direct Ligand Exchange: peptides thiolated na-ewepụ ndị nnọchi anya citrate capping na nanoparticles ọla edo edo edo site na nhazi S – Au bond ozugbo..
- Njikọ njikọ Thioether: AuNP nke Maleimide na-arụ ọrụ na-emeghachi omume na peptide thiols efu iji guzobe njikọ thioether kwụsiri ike..
Maka ndụmọdụ: Mgbe ị na-eji maleimide-thiol cross-linking chemistry, dobe ihe nchekwa mmeghachi omume nke ọma n'ime pH 6.5 ka 7.2. N'elu pH 7.5, Ndị otu maleimide na-efunahụ nhọrọ maka sulfhydryls ma meghachi omume na asọmpi na amines praịmarị n'efu (dị ka ụgbụ akụkụ Lysine ma ọ bụ amines N-terminal), na-eke iche iche, peptide-nanoparticle conjugates na-akọwaghị nke ọma.
Njikwa ogo siri ike: Nkọwa dị mkpa maka Peptides jikọtara ọnụ na-emekọ ihe ọnụ
Peptides ezubere maka nanoconjugation na-eche njikwa ogo siri ike (QC) ihe mgbochi karịa peptides nyocha ọkọlọtọ. Ihe adịghị ọcha nke nwere ike ịdị mma na nyocha nke biochemical nwere ike imebi nkwụsi ike nanoparticle colloidal., kpalite mmụkọta urughuru a na-apụghị ịgbagha agbagha, ma ọ bụ kpalite cytotoxicity na-abụghị nke akọwapụtara.
1. Oke oke ịdị ọcha RP-HPLC (≥98%)
Usoro mkpochapụ agbajiela na-efu otu amino asịd ma ọ bụ abụọ na-enwekarị profaịlụ hydropathy agbanwere.. N'oge mgbanwe ligand, ndị a dị mkpụmkpụ, hydrophobic ihichapụ adịghị arụkọ ọrụ na-adaba n'elu ọla edo, na-agbanwe geometry nkwakọ ngwaahịa dị ukwuu nke oyi akwa ezubere iche ma na-eme ka mgbanwe batch-to-batch na PD-L1 na-ekekọta avidity.. Chromatography Liquid Liquid Opekempe Analytical Reverse-Phase High- Performance Liquid (RP-HPLC) ịdị ọcha nke ≥98% achọrọ mpaghara kacha elu. Peptides nyocha
2. Mass Spectrometry dị elu (HR-LC-MS) & AAA
LC-MS/MS ga-enwerịrịrịrị njirimara usoro, dakọtara ọnụ ọgụgụ monoisotopic theoretical n'ime ± 0.5 Da. Ọzọkwa, nnukwu peptide arọ na-agụnye mmiri tọrọ atọ na mgbochi. Amino Acid Analysis (AAA) ma ọ bụ NMR quantitative (qNMR) dị mkpa iji chọpụta ihe net peptide ọdịnaya (na-emekarị 75% ka 85% nke ngụkọta akọrọ arọ), na-ekwe ka ndị ọkà mmụta sayensị na-emepụta ihe gbakọọ kpọmkwem ọnụ ọgụgụ molar n'oge arụ ọrụ nanoparticle.
3. Mwepụ na mgbanwe TFA Counterion (<1.0% Mwepu)
Ọkọlọtọ RP-HPLC na-eji ịdị ọcha 0.1% trifluoroacetic acid (TFA) dị ka ihe mkpanaaka na-eme mgbanwe. N'ihi ya, A na-ekewakarị peptides sịntetị dị ka nnu TFA. Mgbochi TFA fọdụrụnụ na-ebute nnukwu ihe egwu abụọ na sistemu nanoparticle:
- Colloidal Akwụsịghị: ion TFA efu na-akpaghasị oyi akwa okpukpu abụọ nke electrostatic colloid ọla edo, na-eme ka nchịkọta na mmiri ozuzo ngwa ngwa na-enweghị ike ịgbanwe.
- Nyocha toxicity: TFA fọdụrụnụ na-akpalite mmebi akpụkpọ ahụ sel na-abụghị nke akọwapụtara yana nsi cell na bioassays omenala., ikpuchi ezi nzaghachi mgbochi PD-L1 immunomodulatory.
Ntuziaka nchịkwa sitere na Ụlọ ọrụ ọgwụ na Europe (EMA) na sịntetik Peptides na-ekwu na a ga-achịkwarịrị ma zie ezi ọdịnaya ọdịnaya. Maka nanoconjugation, na-atụgharị nnu TFA ka ọ bụrụ acetate ma ọ bụ hydrochloride (HCl) ụdị nnu site na ion-exchange chromatography ma ọ bụ na-achịkwa 10 okirikiri ịsa mM HCl na-ebelata TFA fọdụrụ n'okpuru 1.0% w/w (kwadoro site na iji USP <503.1> Trifluoroacetic acid (TFA) na Peptides ụkpụrụ) na-emebighị nkwụsi ike nke kemịkal.
4. Endotoxin na njikwa bioburden (<0.25 EU/mg)
Ọgwụ nje endotoxins (lipopolysaccharide, LPS) ewebata n'oge njikọ ma ọ bụ ịdị ọcha na-ejikọta ike na elu nanoparticle ọla edo. Mgbe a na-enye ya dị ndụ, nanoconjugates mmetọ nke endotoxin na-akpalite oke mmiri ozuzo cytokine sistemu yana ịgbalite usoro ahụ ji alụso ọrịa ọgụ., data mgbochi PD-L1 na-agbagwoju anya. Acetyl Hexapeptide 1 Onye nrụpụta
Maka nyocha dabere na cell, Ọkwa endotoxin kwesịrị ịdị n'okpuru 0.5 EU/mg. Maka preclinical dị ndụ ọmụmụ, nkọwa kwesie ka <0.25 EU/mg (gụpụtara ya site na chromogenic Limulus Amebocyte Lysate (LAL) assays dabere na USP <85> / Ph. Euro. 2.6.14 Nnwale Endotoxins nke nje), na-achọ njikọ n'ime nlezianya na-achịkwa, akụrụngwa-nzacha. Mmepe na Ngwa nke Nhọrọ Oxidative mechie mgbanaka na ọtụtụ otu Sulfhydryl
Matriks njikwa ogo Peptide nanoparticle-ọkwa
| Oke QC | Usoro nyocha nyocha | Usoro nnabata | Mmetụta arụmọrụ na Nanoconjugation |
|---|---|---|---|
| Ịdị ọcha kemịkalụ | RP-HPLC (C18 / C8, UV 220 nm) | ≥98.0% normalization mpaghara | Na-egbochi mgbasa ozi adịghị ọcha nhichapụ & njikọ dị iche iche nke saịtị |
| njirimara / Mass | ESI-TOF LC-MS ma ọ bụ HR-MS | Theoretical Mass ± 0.5 Da | Na-akwado iguzosi ike n'ezi ihe nke usoro, disulfide cyclization, & njikọ mgbakwunye |
| Ọdịnaya Peptide Net | Amino Acid Analysis (AAA) / qNMR | 75.0% - 85.0% w/w | Na-agba mbọ hụ na oke stoichiometric peptide-to-gold molar ruru |
| Ọdịnaya TFA fọdụrụnụ | Ion Chromatography / 19F-NMR (USP <503.1>) | <1.0% w/w (Ebumnuche <0.5%) | Na-ewepụ mkpokọta colloid & sel-line toxicity |
| Ọnụ ọgụgụ Thiol efu | Nkọwa nke Ellman (DTNB) / HPLC | ≥95.0% unoxidized -SH | Na-ekwe nkwa nhazi S–Au nke ọma ma ọ bụ njikọta maleimide |
| Endotoxin nke nje bacteria | LAL nyocha (USP <85> / Ph. Euro. 2.6.14) | <0.25 EU/mg (na vivo ọkwa) | Na-egbochi ịgbalite ihe mgbochi ọrịa & sistemu endotoxicity |
Njiri mara Biophysical Post-Conjugation & Nlele nkwụsi ike
Ozugbo peptide dị elu nke Fmoc-synthesized na-ejikọta ya na nanoparticles ọla edo, nkwado biophysical na-akwado na nanoconstruct kwụsiri ike ma na-arụ ọrụ.
Peptide-AuNP Biophysical Validation Suite UV-Vis Absorption DLS & Zeta Charge Bioactivity Assay SPR Red-Shift 2-5nm Hydrodynamic Size PD-L1 Binding IC50
- UV-Vis dị n'elu Plasmon Resonance (SPR) Mgbanwe: Monodisperse 13–15 nm sppherical gold nanoparticles na-egosipụta oke mmịnye SPR siri ike dị nso. 520 nm. Ịmepụta nke ọma nke nnukwu peptide monolayer na-agbakọta onwe ya (SAM) na-abawanye ndetu refractive mpaghara, na-eme ka njirimara 2 nm na 5 nm uhie-ngbanwe (ruo ~522-525 nm) na-enweghị mgbasawanye elu. Mgbasawanye ma ọ bụ mkpochapụ na-egosi mkpokọta colloidal.
- Mgbasa ọkụ dị egwu (DLS) & Zeta nwere ike: DLS na-atụ mmụba nke dayameta hydrodynamic dabara na ogologo nke shei ligand PEG-peptide. Ndepụta nke Polydispersity Index (PDI) <0.2 na-akwado monodispers, ọnụ ọgụgụ na-enweghị mkpokọta. Enwere ike ịtụ Zeta na-ekpughe mgbanwe ụgwọ elu, na-akwado mkpuchi elu.
- Na Vitro PD-L1 Asọmpi Binding Assay: Ekwenyesiri ike na-arụ ọrụ site na ELISA asọmpi ma ọ bụ n'elu Plasmon Resonance megide protein PD-L1 mmadụ recombinant.. Dị ka ọmụmụ na PD-L1 ndị inhibitors peptide ezubere iche bipụtara na PMC, ihe nrụnye ezubere iche nke nwere nnukwu anụrị na-enweta mkpokọta mgbochi mgbochi ọkara (IC50) na nanomolar ruo obere micromolar.
⚠️ Ịdọ aka ná ntị: Ekwela ka ifriizi ihe ngwọta nanoparticle ọla edo na-adịghị arụ ọrụ ma ọ bụ nke na-adịghị mma na-enweghị cryoprotectants kwesịrị ekwesị (eg., 10% trehalose ma ọ bụ sucrose). Nhazi kristal ice na-amanye cores ọla edo ka ọ bụrụ kọntaktị anụ ahụ agaghị agbanwe agbanwe, na-eme ka ọla na-adịgide adịgide sintering.
Ijikọta Synthesis na Nanoconjugation na MOL mgbanwe
Ịsụgharị usoro peptide gbagwojuru anya site na njikọ siri ike ka ọ bụrụ ọgwụgwọ nanoparticle a na-emegharịgharị chọrọ onye mmekọ na-emepụta ihe nwere ọkachamara n'ọzụzụ miri emi na ma peptide chemistry na nhazi usoro..
Dị ka a pụrụ iche nnyocha na mmepe ikpo okwu, MOL mgbanwe na-ejikọta Fmoc SPPS dị elu na ikike bioconjugation dị elu. Ezubere iji kpochapụ ọdịiche teknụzụ dị n'etiti njikọ na nanoconjugation, MOL mgbanwe na-enye: Acetyl Hexapeptide 1 Onye na-ebu ihe
- Ime ụlọ dị ọcha: A na-emepụta mmepụta sịntetik n'ime Klas 100 ụlọ ọcha ultra-sterile, na-eme ka ọkwa endotoxin dị ala nke ukwuu (<0.25 EU/mg kwa USP <85>) dabara adaba maka nyocha mkpụrụ ndụ nwere mmetụta na dị ndụ nanomedicine.
- 300+ Nhọrọ mgbanwe: Mgbanwe zuru oke gbasara saịtị, gụnyere monodisperse PEG linkers (PEG2 ruo PEG36), C-terminal Cys ejiri aka, Lys n'akụkụ-agbụ arụ ọrụ, na mkpado fluorophore/chelator.
- Ngbanwe TFA kwadoro: Usoro mgbanwe mgbanwe mgbanwe akpaaka na-ekwe nkwa <1.0% ihe fọdụrụ TFA (Acetate ma ọ bụ HCl nnu gbanwere site na USP <503.1> ụkpụrụ) kwadoro site na Ion Chromatography siri ike na nnwale 19F-NMR.
- Nkwụsi ike n'okwu enwetara & Arụmọrụ: N'ime nnwale nanoconjugation atụnyere ya na peptides PD-L1 thiolated, MOL Changes 'peptides gbanwere acetate gosipụtara mkpokọta colloid ọla edo efu karịa nlekota nkwụsi ike ụbọchị 30, ebe usoro nnu TFA na-agbanweghi agbanwe gosipụtara oke mmiri ozuzo a na-ahụ anya n'ime 48 awa.
- Scalability enweghị nkebi: Usoro mmepụta na-agbanwe agbanwe na-akwado ndị nyocha site na nyocha usoro nha milligram ruo ọtụtụ gram na kilogram mmepụta ihe CDMO/CRO.
- Nyocha nyocha zuru ezu: A na-ebunye ogbe ọ bụla na akwụkwọ nyocha zuru oke, gụnyere chromatogram LC-MS dị elu, Profaịlụ ịdị ọcha RP-HPLC, yana nsonaazụ nnwale LAL endotoxin enwetara.
Ma ị na-echepụta ọgbọ na-abịa PD-L1 ezubere iche maka nanotherapeutics ọla edo ma ọ bụ na-emepụta conjugates ọgwụ peptide siri ike. (Ndị PDC), iso onye na-ebubata ihe raara onwe ya nye na-arụkọ ọrụ na-eme ka nnwale nnwale ma mee ka njem gị si n'oche ụlọ nyocha gaa na ntụgharị asụsụ ụlọ ọgwụ..
Chọgharịa nhazi usoro omenala na nkọwapụta peptide nanoconjugation dị njikere taa na MOL na-agbanwe njikọ peptide omenala yana ikpo okwu mgbanwe.
